Kintor Pharmaceutical Limited (KNTPF)
OTCMKTS · Delayed Price · Currency is USD
0.3316
0.00 (0.00%)
At close: Feb 5, 2026
Kintor Pharmaceutical Employees
Kintor Pharmaceutical had 136 employees as of June 30, 2025. The number of employees decreased by 32 or -19.05% since the number was reported on December 31, 2024.
Employees
136
Change
-32
Growth
-19.05%
Revenue / Employee
$11,274
Profits / Employee
-$171,478
Market Cap
176.15M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2025 | 136 | -32 | -19.05% |
| Dec 31, 2024 | 168 | -57 | -25.33% |
| Dec 31, 2023 | 225 | -76 | -25.25% |
| Dec 31, 2022 | 301 | -15 | -4.75% |
| Dec 31, 2021 | 316 | 114 | 56.44% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Silence Therapeutics | 116 |
| Vaxart | 105 |
| Northwest Biotherapeutics | 25 |
| CytoDyn | 13 |
| Nuo Therapeutics | 9 |
| ZIVO Bioscience | 7 |
| Vicapsys Life Sciences | 2 |
| Cell Source | 1 |
Kintor Pharmaceutical News
- 2 years ago - Kintor Pharma Announces the Approval for Phase II Clinical Trial of Hedgehog/SMO Inhibitor GT1708F for Treatment of IPF in China - PRNewsWire
- 2 years ago - Kintor Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of GT20029 for Treatment of Androgenetic Alopecia in China - PRNewsWire
- 2 years ago - Kintor Pharma Announces Completion of First Patient Enrollment in Long-term Safety Phase III Trial of KX-826 for Treatment of AGA - PRNewsWire
- 3 years ago - Kintor Pharma Announces Successful Completion of Phase II Clinical Trial of KX-826 for Treatment of Androgenetic Alopecia in the US - PRNewsWire
- 3 years ago - Kintor Pharma Announces 2022 Annual Results and Recent Business Progress - PRNewsWire
- 3 years ago - Kintor Pharma Announces Completion of Subject Enrollment in Phase III Clinical Trial of KX-826 for Treatment of Male Androgenetic Alopecia in China - PRNewsWire
- 3 years ago - Kintor Pharma's KX-826 and GT20029 for Treatment of Androgenetic Alopecia (AGA) and Acne Presented at AAD 2023 - PRNewsWire
- 3 years ago - Kintor Pharma Announces Positive Top-line U.S. Phase I Trial Results of GT20029, the World's First Topical Use PROTAC Compound - PRNewsWire